Welcome to LookChem.com Sign In|Join Free
  • or
Pyrrolidine, 1-[3-(4-bromophenyl)propyl]-, is an organic compound with the chemical formula C11H16BrN. It is a derivative of pyrrolidine, a heterocyclic amine with a five-membered ring containing one nitrogen atom. The compound features a 4-bromophenylpropyl group attached to the nitrogen atom, which introduces a bromine atom at the para position of the phenyl ring. This chemical structure endows the compound with unique properties, making it potentially useful in various applications, such as pharmaceuticals and chemical synthesis. Its molecular weight is 244.16 g/mol, and it is likely to be a solid at room temperature. The presence of the bromine atom and the alkyl chain on the nitrogen atom can influence its reactivity and solubility in different solvents.

4897-54-5

Post Buying Request

4897-54-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

4897-54-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 4897-54-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,8,9 and 7 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 4897-54:
(6*4)+(5*8)+(4*9)+(3*7)+(2*5)+(1*4)=135
135 % 10 = 5
So 4897-54-5 is a valid CAS Registry Number.

4897-54-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-[3-(4-Bromophenyl)propyl]pyrrolidine

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:4897-54-5 SDS

4897-54-5Relevant academic research and scientific papers

Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy) phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): A topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degene

Palanki, Moorthy S. S.,Akiyama, Hideo,Campochiaro, Peter,Cao, Jianguo,Chow, Chun P.,Dellamary, Luis,Doukas, John,Fine, Richard,Gritzen, Colleen,Hood, John D.,Hu, Steven,Kachi, Shu,Kang, Xinshan,Klebansky, Boris,Kousba, Ahmed,Lohse, Dan,Chi, Ching Mak,Martin, Michael,McPherson, Andrew,Pathak, Ved P.,Renick, Joel,Soll, Richard,Umeda, Naoyasu,Yee, Shiyin,Yokoi, Katsutoshi,Zeng, Binqi,Zhu, Hong,Noronha, Glenn

, p. 1546 - 1559 (2008/12/21)

Age-related macular degeneration (AMD) is one of the leading causes of loss of vision in the industrialized world. Attenuating the VEGF signal in the eye to treat AMD has been validated clinically. A large body of evidence suggests that inhibitors targeti

2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS

-

Page/Page column 110-111, (2010/11/29)

Compounds having the general structure (A) are provided. The compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, Vegfr and various other specific receptor and non-receptor kinases. Formula (I):

PYRIMIDINE COMPOUNDS AND METHODS OF USE

-

Page/Page column 114-115, (2010/11/24)

The invention provides pyrimidine compounds having formula (A): The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, and various other specific receptor and non-receptor kinases.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

-

, (2008/06/13)

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 4897-54-5